GSK, one of the UK's largest pharmaceutical companies, announced a £1.9 billion cost-cutting programme on 28 July 2026. The goal is to save that same amount each year by 2029. At the same time, the company is overhauling where it does research in the UK and doubling the number of late-stage drug trials it runs, under its new chief executive Luke Miels (The Guardian; GSK). Late-stage drug trials, called phase 3 trials, are the final big tests a drug goes through before a company asks regulators for permission to sell it. The restructuring will cost £2.4 billion to carry out (GSK). The news came alongside GSK's Q2 2026 financial results, which the company called strong (GSK; QZ).

The plan's centerpiece is a new 300,000 sq ft (28,000 sq metre) research facility on the Cambridge biomedical campus, built by Prologis. More than 1,000 scientists will move there. The labs will support research into cancer, respiratory diseases, liver diseases, vaccines, and HIV (The Guardian). GSK will close its current research site in Stevenage, Hertfordshire, by 2029 and upgrade labs at Ware, shifting some staff there (The Guardian). The company also pledged £400 million in UK life sciences investment over three years (The Guardian).

GSK would not say how many jobs will be cut globally as part of the programme (The Guardian). Earlier in 2026, the company had already disclosed plans to lay off up to 350 research workers across the US and UK (Fierce Biotech; FirstWord Pharma). Around 150 job cuts in Massachusetts, linked to manufacturing changes at GSK's US Cambridge site, were signalled in 2025 (FirstWord Pharma; Fierce Pharma). Whether this new programme adds to or replaces those earlier cuts is unclear.

Miels became CEO at the start of 2026, replacing Emma Walmsley. He had previously been GSK's chief commercial officer (The Guardian). The 28 July announcements are the biggest strategic moves of his time in charge so far. GSK plans to launch 20 phase 3 trials, double what it announced earlier in 2026 (The Guardian). The company is pairing aggressive cost-cutting goals with a much larger late-stage drug pipeline, which suggests pressure to show returns on its research spending rather than just shrinking the budget.

Moving to Cambridge puts GSK in one of Europe's biggest hubs for life sciences. The biomedical campus already has more than 22,000 life sciences workers and over 470 companies in pharmaceuticals, biotech, and AI (The Guardian). AstraZeneca, GSK's larger UK-based rival, announced a £300 million UK investment in April 2026, including a £200 million expansion in Cambridge (The Guardian). AstraZeneca had paused large UK projects in 2025 before changing direction (The Guardian).

The broader context here is a tension that runs across the whole pharmaceutical sector: companies are trying to cut costs while also spending more on developing new drugs. GSK is asking investors to accept a £2.4 billion upfront cost in exchange for £1.9 billion in annual savings, while also putting £400 million into UK facilities and doubling its late-stage trial plans. The bet is that concentrating scientists and technology in one place — a busy innovation hub — will produce drugs faster and more cheaply than spreading research across multiple sites. A useful comparison: imagine a retailer closing several smaller shops to open one large store in the busiest shopping centre. The overhead goes down, but only if that one store can handle all the customers. Whether the savings arrive on time, and whether the expanded drug pipeline actually leads to approved medicines, are the two things that will decide whether this plan was worth the cost. The Stevenage site closure carries political and workforce risks, and GSK's refusal to say how many jobs will go globally makes those risks harder to assess.

It is worth comparing GSK's move with AstraZeneca's 2025 pause and subsequent UK reinvestment. Both companies are betting that the Cambridge biomedical campus will be the centre of gravity for UK pharmaceutical research. GSK's approach is more disruptive: it involves shutting a site entirely and cutting an undisclosed number of jobs, while AstraZeneca has framed its plans as expansion. With two major employers recruiting and moving scientists into the same area, the competitive and labour-market pressures in that corridor will be worth watching as both programmes head toward their 2029 deadlines.